Research

Cellular

KN069 was well tolerated, with predominantly mild-to-moderate gastrointestinal adverse events.

KN069 may be a safe option for weight management in this population.

StrongSupportsmedium confidence
KN069 was well tolerated, with predominantly mild-to-moderate gastrointestinal adverse events.
Jinlian Xie et al. · Diabetes Obesity and Metabolism · 2026

Why this rating

Based on the randomized, double-blind trial design.

Source

A Phase 1, Randomised, Double‐Blind, Placebo‐Controlled Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of <scp>KN069</scp> (a Dual <scp>GLP</scp> ‐ <scp>1R</scp> Agonist and <scp>GIPR</scp> Antagonist) in Male Adults With Overweight or Obesity

Jinlian Xie et al. · Diabetes Obesity and Metabolism · 2026

DOI 10.1111/dom.70794

rct · n=48
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →